Group One Trading’s Protara Therapeutics TARA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$53 Sell
14
-1,283
-99% -$6.1K ﹤0.01% 7431
2026
Q1
$6.76K Sell
1,297
-17,103
-93% -$101K ﹤0.01% 6571
2025
Q4
$98.1K Buy
18,400
+15,500
+534% +$86.2K ﹤0.01% 5028
2025
Q3
$12.6K Buy
+2,900
New +$9.39K ﹤0.01% 7029
2025
Q1
– Sell
-1,394
Closed -$6.23K – 8357
2024
Q4
$7.36K Buy
+1,394
New +$4.5K ﹤0.01% 6244
2024
Q3
– Sell
-2,550
Closed -$5.3K – 7351
2024
Q2
$5.3K Buy
+2,550
New +$7.46K ﹤0.01% 5924

Other funds holding TARA

Group One Trading's TARA Position: Q2 2026 in Review

Group One Trading reduced its Protara Therapeutics (TARA) stake by 99% in Q2 2026, selling an estimated $6.1K and leaving 14 shares worth $53. The position accounts for ﹤0.01% of the portfolio, ranked #7431.

Group One Trading first reported a position in TARA in Q2 2024 and has held it in 6 quarters since. The position peaked at $98.1K in Q4 2025. 119 funds tracked by Wall St. Rank hold TARA as of Q2 2026.

  • Group One Trading held 14 shares of Protara Therapeutics worth $53 as of Q2 2026.
  • Group One Trading sold 1,283 Protara Therapeutics shares in Q2 2026, an estimated $6.1K.
  • Protara Therapeutics made up ﹤0.01% of Group One Trading's portfolio in Q2 2026, its #7431 holding.
  • Group One Trading first reported a position in Protara Therapeutics in Q2 2024 and has held it in 6 quarters since.
  • Group One Trading's Protara Therapeutics position peaked at $98.1K in Q4 2025.
  • 119 funds tracked by Wall St. Rank held Protara Therapeutics as of Q2 2026.

Based on Group One Trading's 13F filing for Q2 2026, filed 14 Aug 2026.